Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 2/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499966 | 0.87 | GABRA1 (0.39) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL7116775 | 0.86 | CHRNA1 (0.46) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL7507181 | 0.83 | CHRNA1 (0.52) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL7503621 | 0.83 | CYP11B1 (0.41) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL7497459 | 0.83 | CYP11B1 (0.41) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL7503875 | 0.79 | GAA (0.37) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL6331195 | 0.79 | LMNA (0.45) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL7503669 | 0.79 | CHRNA7 (0.50) | CHRNA1CHRNA7CHRNB2CHRNA4GAA | |
| SCHEMBL6331196 | 0.79 | LMNA (0.45) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL7500880 | 0.79 | CHRNA1 (0.50) | CHRNA1CHRNA7CHRNB2CHRNA4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1198803-C | Heterocyclic compounds having effect of activating nicoting acetylchloine alpha 4 beta 2 receptor | FIRST SUNTORY PHARMACEUTICAL L (JP) | 2005-04-27 | — | — | CN | claimed |
| CN-1349506-A | Heterocyclic compounds having effect of activating nicoting acetylchloine alpha 4 beta 2 receptor | SUNTORY LTD (JP) | 2002-05-15 | — | — | CN | claimed |
| EP-0970050-B1 | PROCESS FOR THE PREPARATION OF 10,11-DIHYDRO-5H-DIBENZO A,D]CYCLOHEPT-5-ENES AND DERIVATIVES THEREOF | ROLABO SL (ES) | 2001-10-24 | — | — | EP | claimed |
| EP-0857725-B1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2001-07-25 | — | — | EP | claimed |
| US-6020335-A | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC (US) | 2000-02-01 | — | — | US | claimed |
| EP-0857725-A1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-08-12 | — | — | EP | claimed |
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | SUNTORY LIMITED | 2002-03-07 | — | — | US | disclosed |
| EP-1176141-A1 | HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR | SUNTORY LIMITED (JP) | 2002-01-30 | — | — | EP | disclosed |
| CN-1332726-A | Pyrrolidine compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2002-01-23 | — | — | CN | disclosed |
| EP-0857725-B1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6020335-A | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0857725-A1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-08-12 | — | — | EP | disclosed |
| US-4551451-A | Tricyclic derivatives of 5,6-dihydro-11H-dibenzo (b,e) azepin-6-one having pharmacological activity | A. MENARINI S.A.S. (IT) | 1985-11-05 | — | — | US | disclosed |
| US-4551451-A | Tricyclic derivatives of 5,6-dihydro-11H-dibenzo (b,e) azepin-6-one having pharmacological activity | A. MENARINI S.A.S. (IT) | 1985-11-05 | — | — | US | disclosed |
| EP-0089322-A1 | Tricyclic derivatives of 5,6-dihydro-11H-dibenzo(B,E)azepin-6-one having pharmacological avtivity, and method for their preparation | A. Menarini S.a.S. (IT) | 1983-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | CHRNA2, CHRNA7, CHRNB2 | CHRNA1 6/4885CHRNA7 2/4885CHRNB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.